pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2031-01-31
Target enrollment:
Participant gender:
Summary
RODEO is a window of opportunity trial using dostarlimab in patients with newly diagnosed high-risk (stage 2-4) endometrial cancer who are suitable for primary surgery. Patients will receive 2 doses of dostarlimab (500mg IV day 1 and day 22) prior to surgery. The primary objective is to assess the pathological response rate to pre-operative dostarlimab and the secondary objectives are to assess the feasibility, toxicity, safety and efficacy of pre-operative dostarlimab.